News
Public · Published
JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $79 from $78
JP Morgan kept its Neutral rating on Halozyme Therapeutics and raised its price target to $79 from $78, a 1.3% increase. That target implies a 38.7% downside from the November 2 close of $128.95.
Published:
Updated:
What happened
JP Morgan kept its Neutral rating on Halozyme Therapeutics and raised its price target to $79 from $78, a 1.3% increase. That target implies a 38.7% downside from the November 2 close of $128.95.
Confirmed
Global impact / market context
The new target sits far below the recent share price, so JP Morgan sees limited upside even after a small increase. A Neutral rating tells clients not to expect a big move, which can temper buying interest from investors who follow analyst ratings.
Analyst inference
Recent analyst targets on Halozyme range from $78 to $130, showing wide disagreement about the company's worth. Two other firms rate it Buy with $130 targets, so JP Morgan's Neutral view is the most cautious among the three recent notes.
Analyst inference
What to watch
- The November 2 close of $128.95 was far above JP Morgan's $79 target, so watch whether the share price moves closer to that target over time. Confirmed
- Watch whether other analysts change their $130 targets or Buy ratings, since a shift by either firm would change the balance of opinion. Proposed
- Watch Halozyme's next financial results, because stronger revenue or profit could push targets higher, while weaker results could support JP Morgan's cautious stance. Analyst inference
Evidence
- Original source link unavailable